Drug intelligence / Profile preview

CP-39,332

Development stage: Unknown
Lead developer: Pfizer
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

CP-39,332 is a small molecule drug that acts as a serotonin-norepinephrine reuptake inhibitor (SNRI). It belongs to the aminotetralin class and is one of several monoamine reuptake inhibitor stereoisomers related to tametraline. The compound was developed by Pfizer but was never marketed. Its mechanism involves inhibiting the reuptake of both serotonin and norepinephrine, increasing their levels in the synaptic cleft and thereby enhancing neurotransmission. Stereoisomers of CP-39,332 include tametraline (1R,4S), CP-24,442 (1S,4R), CP-22,185 (cis), and CP-22,186 (trans), each with varying effects on monoamine reuptake[2][4][5][8].

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on CP-39,332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-39,332.

Explore the full profile